Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Tag archive for ‘Brincidofovir in AdVise’

Chimerix: Thinking on the Stock in the Aftermath of Results from the AdVise Trial (CMRX, $4.95)

Overview In a report published on April 14th I recommended purchasing Chimerix at a┬áprice of $5.67. The catalyst for my recommendation was the pending release of data from the AdVise trial of brincidofovir in life threatening adenoviral infections in children and adults. I estimate that the US addressable market for this indication as perhaps $150 […]